OBI Pharma Inc. to attend 2019 investor conference hosted by Yuanta
1.Date of the event: Dec 20, 20182.Time: 15:00:00 NST3.Location: The Westin Taipei4.Summary: OBI Pharma Inc. to attend 2019 investor conference hosted by Yuanta 5.Any other matters that need to be …
OBI Pharma Inc. to attend the Citi’s 2018 Global Healthcare Conference
1.Date of the event: Dec 5 ~ Dec 6, 2018 2.Time: 22:00:00 NST 3.Location: The Lotte New York Palace 4.Summary: OBI Pharma Inc. to attend the Citi’s Adhd Drugs Healthcare …
Announcement of the resolution of the board of directors of the company to issue common shares through rights offering
Date of the board of directors resolution: Nov 30, 2018 Source of capital increase funds: issue common shares through rights offering Number of shares issued: 15,000,000 common shares Par value …
OBI Pharma Inc. to attend the 2018 Asia Pacific Healthcare Forum, hosted by Goldman Sachs
1.Date of the event: Nov 27 ~ Nov 28, 2018 2.Time: 09:00:00 CST 3.Location: Jw Marriott Hotel Hong Kong Level 3 Ballroom 4.Summary: OBI Pharma Inc. to attend the 2018 …
Clarification on the news article by Up Media and other media groups
Date of occurrence of the event: Nov 23, 2018 Company name: OBI Pharma Inc./ AP Biosciences Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office/subsidiary Reciprocal …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
First Orphan Drug Designation for OBI-888, a novel first-in-class Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types. TAIPEI, Taiwan, November 21, 2018 /PRNewswire/ — OBI Pharma, …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
Date of occurrence of the event: Nov 21, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong
Date of occurrence of the event: Nov 15, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Investigational Device Exemption (IDE) for the development of OBI-888 was approved by the US Food and Drug Administration (FDA) for its use in OBI-888 Phase I cohort expansion phase
Date of occurrence of the event: Nov 12, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States
Date of occurrence of the event: Nov 02, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …